The Global Rheumatoid Arthritis Therapeutics Market is estimated to grow at a CAGR of 4.8% during the forecast period 2018-2025. As per the analysis, the global market was valued $23,822.5 Million in the year 2017 and is estimated to reach $33,988.2 million by the end of the year 2025. The market analysis was done by research analyst through detailed qualitative and quantitative analysis.
The Global Rheumatoid Arthritis Therapeutics Market is driven by various growth factors such as increase in number of geriatric populations worldwide—high prevalence of rheumatoid arthritis among aged population. Improvement in diagnostic procedures, spread of various awareness programs and increasing number of skilled healthcare professionals are further boosting the market growth for the forecast period.
The research study includes the detailed analysis of the global rheumatoid arthritis therapeutics market. The detailed analysis is based upon various measures, models and methods. Some of the majorly adopted economic models are SWOT analysis, PEST analysis, Porter’s Five Force Model and other analytical models. The qualitative analysis of the global market includes study of the major market determinants such as market drivers, numerous challenges, market restraints, upcoming market opportunities and various market trends.
The global rheumatoid arthritis therapeutics market is majorly segmented on the basis of product and distribution channel. These major market segments are further categorized into various sub-segments to study the market in detail. The product segment of the market is sub-segmented into Biologics and Non-Biologics. The Non-Biologics segment is further categorized into NSAIDs, DMARDs and others. The Distribution Channel Segment of the global market is sub-segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy.
On the basis of geographical segmentation, the global rheumatoid arthritis therapeuticsmarket was studied across North America (U.S., Canada); Europe (Germany, UK, France, Italy, Spain, Scandinavia and Rest of Europe); Asia Pacific (China, India, Japan, Australia, Southeast Asia and Rest of Asia Pacific); Latin America (Brazil, Mexico and Rest of Latin America); Middle East & Africa and Rest of the World. As per the analysis, North American market is dominating the global market, owing to increasing prevalence of rheumatoid arthritis in the region, rising awareness about the disorder and focus of regional government on boosting healthcare services and medical facilities. On the other hand, the Asia Pacific rheumatoid arthritis therapeuticsmarket is estimated to grow at a significant growth rate with fastest CAGR. The regional growth is attributed to launch of new drugs in biologics that are majorly used in the treatment of rheumatoid arthritis. The growth of the APAC market is also influenced by increasing investment of the healthcare and medical infrastructure in emerging regions.
The research report offers detailed analysis of company profiles. The company profile section of the research study includes various sub-sections that include Overview, Products and Services, SWOT Analysis, Recent Developments, Strategies and Financials. Some of the key companies included in the research study are:
Gilead Sciences, Inc.
Eli Lilly and Company
Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Publisher : BlueWeave Consulting